Prostate Cancer SPORE
Sarki Abdulkadir, MD, PhD
Maha Hussain, MD
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University was awarded a five-year, $9.2 million grant renewal from the National Cancer Institute (NCI) for its continued leadership of a Specialized Programs of Research Excellence (SPORE) in Prostate Cancer.
Led by co-principal investigators Sarki Abdulkadir, MD, PhD, and Maha Hussain, MD, the multi-center consortium provides an integrated scientific environment that leverages the expertise and resources of its investigators to conduct highly translational research projects. First funded in 2001, Lurie Cancer Center’s Prostate Cancer SPORE is one of only seven in the country, and the only one in Illinois.
The Prostate Cancer SPORE brings together basic scientists, clinicians, pathologists, biostatisticians, bioinformaticians, and patient advocates to advance collaborative research projects that will be carried out by investigators at the Lurie Cancer Center, University of Chicago Comprehensive Cancer Center and NorthShore University HealthSystem. In addition, the interdisciplinary teams will design and conduct innovative clinical trials aimed at improving outcomes and overall quality of life for patients with prostate cancer.
The SPOREs are a cornerstone of the NCI’s efforts to promote collaborative, translational cancer research. The projects supported by the grant will focus on two urgent issues in prostate cancer today, led by co-investigators with complementary basic and clinical science expertise.
Learn More About the SPORE
- Our Team
- Career Enhancement
- Patient Advocacy Group
- Diversity in Men’s Health Committee
- Projects & Core Facilities
- Developmental Research Program
- Awards
Visit this page for more information on data and specimen requests within the SPORE.
News
Annual Chung Lee Lecture was held on October 1, 2024
The lecture featured Neil Bander, MD of Weill Cornell Medical College. He serves as Professor of Urologic Oncology at Weill Cornell Medicine and member at Memorial Sloan-Kettering Cancer Center. Dr. Bander pioneered the development of PSMA-targeted imaging agents and therapeutics, transforming the prostate cancer landscape.